miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression

Breast cancer is the most common type of malignancy in women, which remains a significant health concern worldwide. Gemcitabine is a frequently applied anticancer pharmacological agent. However, the efficacy of gemcitabine is limited by chemoresistance. In the present study, a combination of reverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yingqi, Tao, Li, Liang, Junwei, Qiao, Yashun, Liu, Weiwei, Yu, Haina, Yu, Xinghui, Liu, Lanfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388565/
https://www.ncbi.nlm.nih.gov/pubmed/32765654
http://dx.doi.org/10.3892/etm.2020.8770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388565/
https://www.ncbi.nlm.nih.gov/pubmed/32765654
http://dx.doi.org/10.3892/etm.2020.8770

Ejemplares similares